The addition of valsartan to optimized therapy in a cohort of Japanese patients with coronary heart disease and hypertension provides. Description: RETRACTION: The editors of the European Heart Journal have retracted the article reporting data/results of the Jikei Heart Study. The Lancet has formally retracted the Jikei Heart Study paper, originally published in The retraction had been widely anticipated for more.
|Published (Last):||7 July 2012|
|PDF File Size:||7.35 Mb|
|ePub File Size:||18.19 Mb|
|Price:||Free* [*Free Regsitration Required]|
Sum and substance in the Jikei Heart Study. We wrote again on June 4 and June 19 asking when the investigation might be completed. He held the position until Sorry, your blog cannot share posts by email. There should be some accountability here by executuves at Novartis. The primary endpoint will be the onset of any cardiovascular jikri.
Several recent clinical trials have demonstrated that angiotensin II receptor blockers ARBs have cardiovascular as well as renal protective effects. An investigating committee headed by Professor Hashimoto from Jikei University was established. Improved prognosis would confirm the hfart of angiotensin II receptor blockers in the treatment of the cardiovascular disease in Japanese patients. This is outragenous given all those incomes come from healthinsurance and copay form patients.
Learn how your comment uikei is processed.
Matsubara is not an author on the Jikei study. Given this finding, we now wish to retract the Jikei Heart Study on the grounds that we no longer have confidence in the published results.
Lancet retracts Jikei Heart Study of valsartan following investigation – Retraction Watch
Secondary endpoints will include death from any cause, changes in left ventricular size and function, renal function, changes in neuro-hormonal levels and quality-of-life assessments. The government is now investigating how to recover monies from Novaritis, a company obtaines so much moneny based on false and fabrictated data. This site uses Akismet to reduce spam.
Concerns about the Jikei Heart Study.
The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin II receptor blocker, in addition to conventional treatment, will improve the prognosis of Japanese patients with cardiovascular diseases hypertension, ischemic heart disease, congestive heart failure. But we soon became aware that there was concern in Japan about the trial.
In October,we received correspondence heaft concern about the similarity jikek the standard deviations of the mean blood pressure measurements in the two studies, and we invited the authors to comment.
We became aware of this development on April 29,and on May 2 we wrote to Jikei University asking for details of the investigation and requesting that we be kept informed. The report also comments on the affiliation of the person entrusted with the statistical analysis, Nobuo Shirahashi. It is therefore important to verify that the results of these studies are also valid for Japanese patients. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: Dr Azam also told us: Our attempts to obtain a response from Mr Shirahashi were hindered by his recent retirement from Novartis, but the Global Head of Medical Affairs, Dr Usman Azam, did share with The Lancet that Mr Shirahashi had been employed by Novartis throughout the period of the trial and its publication.
Papers on potential cancer drugs retracted for image manipulation. Although we were initially satisfied with their response, in we published a letter from Dr Yui reporting further concerns.
Lancet retracts Jikei Heart Study of valsartan following investigation
The follow-up period will be three years. The Lancet deserves a tip of our hat for such a detailed note. Valsartan in a Japanese population with hypertension and other cardiovascular disease Jikei Heart Study: Of course, The Lancet has been burned before Wakefield… and this is a clinical trial not basic science — hence sanity has prevailed.
Eur Heart J ; Sub-studies will explore the effect in sttudy with diabetes mellitus, hyperlipidemia and the effects of combination of drugs. Your email address will not be published.
Accumulated sales of Jikwi in Japan reaches 12 billion dollars US! Leave a Reply Cancel reply Your email address will not be published. The report identifies concern over the reliability of the blood pressure data: We wrote again on July 31 after we were made aware that a press conference had been held.
If the CNS journals did jikdi right thing, we would have seen several more retractions recently McGill etc. Asian patients including Japanese were under-represented in these trials, however, and no large-scale clinical trials of ARBs have yet been performed in Japan.
Another outrageous and potentiall quite dangerous violoation jiki medical, scientific, and human ethics by Big Pharma hikei to sell their products. Larry Husten, at Cardiobrief, has been following the story in detail, and notes that the saga began with questions about papers by Hiroaki Matsubarawho now has eight retractions. Too much skin in the game, as duplications force retraction of psoriasis paper.
I hope many more journals will take the same detailed approach.